Lamivudine and Zidovudine Tablets and Pexidartinib Hydrochloride
Determining the interaction of Lamivudine and Zidovudine Tablets and Pexidartinib Hydrochloride and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with pexidartinib. Concomitant use of other potentially hepatotoxic agents may potentiate the risk of liver injury. The mechanism of hepatotoxicity is unknown, its occurrence cannot be predicted, and it is unknown whether liver injury occurs in the absence of increased transaminases. In one study, 5% of patients who received pexidartinib developed signs of serious liver injury (elevated serum transaminases greater than 3 times the upper limit of normal (ULN) and total bilirubin greater than 2 times ULN). In these patients, peak ALT ranged from 6 to 9 times ULN, peak total bilirubin ranged from 2.5 to 15 times ULN, and ALP was greater than 2 times ULN. Liver transaminases and total bilirubin improved to less than 2 times ULN in these patients 1 to 7 months after discontinuing pexidartinib. MANAGEMENT: The use of pexidartinib with other potentially hepatotoxic agents should be avoided. Patients treated with pexidartinib should have liver function tests, including AST, ALT, total bilirubin, direct bilirubin, ALP, and gamma-glutamyl transferase (GGT), prior to initiation of pexidartinib, weekly for the first 8 weeks, every 2 weeks for the next month, and every 3 months thereafter. Pexidartinib therapy may require a dosage reduction, to be withheld, or permanently discontinued based on the severity of the hepatotoxicity. A recurrence of increased serum transaminases, bilirubin, or ALP may occur upon rechallenge with a reduced dose of pexidartinib. Liver function tests should be performed weekly for the first month after rechallenge. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. References "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Professional:GENERALLY AVOID: Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with pexidartinib. Concomitant use of other potentially hepatotoxic agents may potentiate the risk of liver injury. The mechanism of hepatotoxicity is unknown, its occurrence cannot be predicted, and it is unknown whether liver injury occurs in the absence of increased transaminases. In one study, 5% of patients who received pexidartinib developed signs of serious liver injury (elevated serum transaminases greater than 3 times the upper limit of normal (ULN) and total bilirubin greater than 2 times ULN). In these patients, peak ALT ranged from 6 to 9 times ULN, peak total bilirubin ranged from 2.5 to 15 times ULN, and ALP was greater than 2 times ULN. Liver transaminases and total bilirubin improved to less than 2 times ULN in these patients 1 to 7 months after discontinuing pexidartinib.
MANAGEMENT: The use of pexidartinib with other potentially hepatotoxic agents should be avoided. Patients treated with pexidartinib should have liver function tests, including AST, ALT, total bilirubin, direct bilirubin, ALP, and gamma-glutamyl transferase (GGT), prior to initiation of pexidartinib, weekly for the first 8 weeks, every 2 weeks for the next month, and every 3 months thereafter. Pexidartinib therapy may require a dosage reduction, to be withheld, or permanently discontinued based on the severity of the hepatotoxicity. A recurrence of increased serum transaminases, bilirubin, or ALP may occur upon rechallenge with a reduced dose of pexidartinib. Liver function tests should be performed weekly for the first month after rechallenge. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.
- "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Generic Name: lamivudine / zidovudine
Brand name: Combivir
Synonyms: Lamivudine and zidovudine, Lamivudine and Zidovudine
Generic Name: pexidartinib
Brand name: Turalio
Synonyms: Pexidartinib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Lamivudine and Zidovudine Tablets-Pfizerpen
- Lamivudine and Zidovudine Tablets-Pharaon Tea
- Lamivudine and Zidovudine Tablets-Pharmorubicin Pfs
- Lamivudine and Zidovudine Tablets-Phazyme
- Lamivudine and Zidovudine Tablets-Phazyme Liquid Gas Relief, Maximum Strength
- Lamivudine and Zidovudine Tablets-Phena-Plus
- Pexidartinib Hydrochloride-Lamivudine Oral Solution
- Pexidartinib Hydrochloride-Lamivudine Tablets
- Pexidartinib Hydrochloride-Lamotrigine
- Pexidartinib Hydrochloride-Lamotrigine Chewable Dispersible Tablets
- Pexidartinib Hydrochloride-Lamotrigine Chewable Tablet
- Pexidartinib Hydrochloride-Lamotrigine Extended Release Tablet